Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 8/20 | 0.58 |
| ▸ | PARP10 | Q53GL7 | 6/20 | 0.58 |
| ▸ | PARP14 | Q460N5 | 4/20 | 0.58 |
| ▸ | PARP15 | Q460N3 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 6/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.55 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.55 |
| ▸ | RELA | Q04206 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2085437 | 1.00 | PARP1 (0.58) | PARP1PARP10PARP14PARP15MEN1 | |
| SCHEMBL2085438 | 1.00 | PARP1 (0.58) | PARP1PARP10PARP14PARP15MEN1 | |
| SCHEMBL2086187 | 0.90 | MEN1 (0.62) | PARP1PARP10PARP14PARP15MEN1 | |
| SCHEMBL2086185 | 0.90 | MEN1 (0.62) | PARP1PARP10PARP14PARP15MEN1 | |
| SCHEMBL16790671 | 0.90 | MEN1 (0.60) | MEN1KMT2AMAPTALDH1A1NPC1 | |
| SCHEMBL18929474 | 0.89 | MEN1 (0.55) | MEN1KMT2AMAPTALDH1A1NPC1 | |
| SCHEMBL15538768 | 0.87 | MEN1 (0.58) | PARP1PARP10PARP14MEN1KMT2A | |
| SCHEMBL2084371 | 0.87 | IMPDH2 (0.55) | MEN1KMT2AMAPTALDH1A1NPC1 | |
| SCHEMBL2084374 | 0.87 | IMPDH2 (0.55) | MEN1KMT2AMAPTALDH1A1NPC1 | |
| SCHEMBL16790669 | 0.86 | MEN1 (0.52) | MEN1KMT2AMAPTALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250144056-A1 | ANTIMICROBIAL HOST DEFENSE PEPTIDE-INDUCING COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF | BOARD OF REGENTS FOR THE OKLAHOMA AGRICULTURAL AND MECH COLLEGES (US) | 2025-05-08 | — | — | US | claimed |
| WO-2023147573-A2 | ANTIMICROBIAL HOST DEFENSE PEPTIDE-INDUCING COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF | BOARD OF REGENTS FOR THE OKLAHOMA AGRICULTURAL AND MECHANICAL COLLEGES (US) | 2023-08-03 | — | — | WO | claimed |
| EP-3784232-B1 | IMPROVED METHODS FOR INDUCING TISSUE REGENERATION AND SENOLYSIS IN MAMMALIAN CELLS | AGEX THERAPEUTICS INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250144056-A1 | ANTIMICROBIAL HOST DEFENSE PEPTIDE-INDUCING COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF | BOARD OF REGENTS FOR THE OKLAHOMA AGRICULTURAL AND MECH COLLEGES (US) | 2025-05-08 | — | — | US | disclosed |
| CN-112955141-B | Improved method for inducing tissue regeneration and senescent cell lysis in mammalian cells | AGEX治疗公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20250011881-A1 | MYC-HSF1 DUAL AMPLIFICATION AS A BIOMARKER FOR CANCER TREATMENT | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2025-01-09 | — | — | US | disclosed |
| US-20240350553-A1 | METHODS FOR MODULATING THE REGENERATIVE PHENOTYPE IN MAMMALIAN CELLS | AGEX THERAPEUTICS INC (US) | 2024-10-24 | — | — | US | disclosed |
| US-20240309458-A1 | MYC-HSF1 DUAL AMPLIFICATION AS A BIOMARKER FOR CANCER TREATMENT | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-09-19 | — | — | US | disclosed |
| EP-4415743-A1 | METHODS FOR MODULATING THE REGENERATIVE PHENOTYPE IN MAMMALIAN CELLS | Reverse Bioengineering, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| US-20230265432-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE MYELOID LEUKEMIA | Sanford Burnham Prebys Medical Discovery Institute | 2023-08-24 | — | — | US | disclosed |
| WO-2023147573-A2 | ANTIMICROBIAL HOST DEFENSE PEPTIDE-INDUCING COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF | BOARD OF REGENTS FOR THE OKLAHOMA AGRICULTURAL AND MECHANICAL COLLEGES (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023064577-A1 | METHODS FOR MODULATING THE REGENERATIVE PHENOTYPE IN MAMMALIAN CELLS | AGEX THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | Frequency Therapeutics, Inc. | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | OTC, EXOSC5, ENTPD5 | PARP1 3668/4885PARP10 3037/4885PARP14 4070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.